皮肤病学

With deep scientific acumen and rich medical expertise, our global contract research organization provides patient-centric dermatology solutions, cutting-edge counsel and enterprise-wide centers of excellence that yield true value in the form of transformative insights and applied market impact for your dermatology product. 

通过与我们开展合作，推动您的皮肤病学项目取得进展。 Together, we complement your scientific expertise and inspire patient-centric solutions across many dermatological indications and study phases.

Therapeutic experience

您需要一个可以预见与研究相关的潜在挑战的合作伙伴。徕博科在皮肤病学领域拥有广泛的全球治疗和运营经验。此全球经验涵盖163项研究，涉及过去五年中53个国家2,831个研究中心的28,092名患者。

我们的医学专家团队专门从事各种药品和化妆品研发，其专业知识、经验和领导才能可为您的项目创造更多价值。 Working as a cross-functional group, our team collaborates with you to provide dermatological advice from medical, operational, regulatory and cost-efficiency perspectives. 您可以利用我们与行业领导者（包括摄影和皮肤病理学核心实验室）之间的合作关系来提供洞见和战略指导，从而带来更好的患者体验，改善临床结果并加快监管审批。

Dermatology assessment scales and photography

如要成功开展临床试验，您需要使用研究者量表、患者报告的结果以及摄影成像对皮肤病学终点进行评估。 Rely on our expertise to select the appropriate disease-specific assessments for your trial as we focus on ensuring the quality of data and integration into electronic data capture systems.

Understanding the patient

The disease burden for a dermatology patient encompasses both physiological and psychosocial dimensions with significant impact on quality of life (QoL). Labcorp understands this complex interaction and is committed to the advancement of dermatological health through clinical development. 因此，我们与在皮肤病学试验方面拥有丰富经验的皮肤科医生开展合作，他们深切理解疾病为患者带来的负担。

As with any trial, it is important to take into account the patient perspective in patient enrollment and understand that dermatology trials require extra attention. Dermatological conditions are multi-faceted as they not only impact QoL, but also span across all age groups with varying sensitivities. 例如，成年患者的招募和保留要求可以预见地不同于儿科和青少年患者的招募，因此，需要专业化护理并体贴患者及其家人。 With the help of our dedicated rare disease and pediatric team, we are perfectly aligned to assist you with clinical development strategy.

In addition to the rare disease and pediatric team, Labcorp also has direct patient feedback and has conducted proprietary "voice of the patient" outreach across a wide variety of conditions, including those in dermatology. 这些见解可进一步用于制定患者友好型方案，并更好地了解纳入和排除标准对患者招募和保留的影响。

Access to experienced sites and patients

Access to experienced sites and patients is key to a successful trial and is particularly true in the competitive environments. Our Xcellerate® Forecasting and Site Selection tool is one of the largest in the pharmaceutical industry and provides Labcorp with unique capabilities to optimize site selection based on industry-wide metrics. This information ensures that low-performing sites are eliminated from the outset and resources are refocused for optimal efficiency.

在美国，徕博科还可以访问庞大的患者和临床医生实验室测试值数据库。该数据库覆盖每天处理的超过500,000份样本，来自美国790,000位临床医生共计超过160亿的测试结果。通过这些数据，徕博科可提供独特的解决方案，了解研究纳入/排除标准的影响并确定患者群以找到最佳潜在研究者。

Xcellerate®数据和徕博科数据的结合体现了在找到合适的研究中心以招募合适的患者方面的强大实力。 High-performing sites on previous dermatology studies (searchable by indications) identified from our Xcellerate® database can be cross-referenced with the Labcorp dataset showing the location of patients with an International Classification of Diseases diagnosis code of interest. In this way, high-performing sites can be identified and cross-referenced to areas of high patient density. 这两种专有的数据来源和工具为徕博科独有，可为您找到合适的研究中心提供宝贵见解。